hHLA Promoter Sequence for Microglia-Specific Transgene Expression
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current gene transfer vectors, particularly lentiviral vectors, fail to efficiently and sufficiently express transgenes in immune cell types such as CNS-associated myeloid/microglia-like cells derived from HSC transplantation, necessitating a promoter sequence that can regulate gene expression effectively in these cells.
Innovation Solution
A synthetic promoter sequence, hHLA, is designed based on the human HLA-DRA gene's regulatory region, incorporating specific DNA motifs and epigenetic markers to ensure minimal basal transcription and high inducibility upon microglia activation, adapted for use in lentiviral vectors to drive transgene expression in immune cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If conventional promoter sequences are used in lentiviral vectors, then vector production and transduction are simplified, but transgene expression efficiency in immune cell types (microglia-like cells) is insufficient
Solution Approach 1:
The promoter sequence is divided into distinct functional modules: a core promoter region (positions -50 to +50 relative to TSS) containing essential transcription initiation elements, and upstream regulatory regions (positions -500 to -50) containing enhancer elements and transcription factor binding sites. This segmentation allows each region to be optimized independently for its specific function while maintaining overall efficiency.
Solution Approach 2:
Different regions of the promoter are assigned specific functional qualities: the core promoter region is designed for high basal transcription activity with optimized TATA box and initiator elements, while upstream regions contain cell-type-specific enhancer elements that confer microglia-specific expression. This local differentiation of functional quality enables both high expression efficiency and cell-type specificity.
2Productivity
If strong constitutive promoters are used to drive high transgene expression, then expression level increases, but regulated control of expression (inducibility upon microglia activation) is lost
Solution Approach 1:
The promoter incorporates dynamic regulatory elements that allow the expression level to change in response to cellular activation state. Specifically, NF-κB binding sites and AP-1 binding sites in the upstream region enable the promoter to transition from a basal state to a highly induced state upon microglia activation, providing dynamic adaptability while maintaining high expression capacity.
Solution Approach 2:
The promoter design includes binding sites for transcription factors that respond to inflammatory signals (NF-κB, AP-1, STAT3), creating a feedback mechanism where the expression level is automatically adjusted based on the activation state of microglia. This ensures high expression during inflammation while maintaining lower basal expression during homeostasis.
3Productivity
If promoter sequences are optimized for high expression in microglia cells, then transgene expression efficiency improves, but applicability to other cell types may be reduced
Solution Approach 1:
The promoter contains both universal core promoter elements (TATA box, initiator, downstream promoter element) that function in diverse cell types, and cell-type-specific regulatory elements (microglia-specific enhancers, hematopoietic transcription factor binding sites) that confer microglia preference. This local differentiation allows the promoter to maintain broad applicability while achieving optimized performance in target cells.
Solution Approach 2:
The core promoter region is designed with universal transcription initiation elements that can function in multiple cell types, while the upstream regulatory regions provide cell-type-specific control. This multi-functional design allows the same promoter sequence to drive expression in both microglia and other cell types, providing versatility without sacrificing microglia-specific efficiency.
Data Source
AI summary
The present invention relates to a promoter sequence for efficient and sufficient expression of transgenes as well as to gene transfer vectors comprising said promoter sequence for use in therapy. In particular, the present invention relates to lentiviral vectors that provide gene therapy for pathological conditions of the central nervous system.